Why Does Wet Granulation Outperform Direct Compression for Niclosamide-Piperazine Tablets?

The incorporation of niclosamide-piperazine veterinary grade API into compressed tablet dosage forms presents measurable process constraints that arise principally from the divergent physicochemical profiles of the two molecules. Niclosamide, a salicylanilide derivative with a melting point within the range of 225–230°C (with decomposition) and intrinsic aqueous solubility of approximately 5–8 mg/L at 25°C, exhibits poor inherent compressibility when subjected to direct compression at industrial scale because the needle-like crystal morphology induces a high elastic recovery ratio during the decompression phase of each compression cycle. Piperazine free base demonstrates hygroscopicity with critical relative humidity values reported below 55% at 25°C, and the free base form undergoes partial hydrate formation when exposed to ambient moisture during roller compaction or direct compression holding periods. These properties dictate that direct compression is rarely suitable for formulations containing niclosamide at mass fractions exceeding 20% w/w of total tablet weight. Wet granulation using a high-shear granulator equipped with a chopper blade operating at 1500–2500 rpm provides the necessary densification of the niclosamide fraction, while the binder solution—typically polyvinylpyrrolidone K30 at 3–5% w/w dissolved in isopropanol-water (80:20 v/v) or purified water alone—minimizes additional moisture loading onto the hygroscopic piperazine component. The granulation endpoint is assessed by torque response or impeller power consumption; over-granulation beyond the endpoint produces granules exceeding 1000 µm in mean particle diameter, which subsequently exhibit unacceptable weight variation during high-speed compression at production speeds exceeding 50,000 tablets per hour. Drying of the granulate in a fluid-bed dryer with inlet air temperature maintained at 50–60°C and product temperature monitored to remain below 45°C prevents accelerated decomposition of niclosamide, which is documented to undergo measurable degradation under prolonged exposure to elevated temperatures due to thermal stress on the salicylanilide amide bond. Target residual moisture content of the dried granulate falls between 1.5% and 2.5% w/w, a value that balances tablet ejection forces against the known moisture sensitivity of the piperazine fraction. Lubrication with magnesium stearate at 0.5–1.0% w/w in a V-blender or bin blender for 3–5 minutes prevents over-lubrication, which would otherwise retard dissolution of the poorly soluble niclosamide fraction due to formation of a hydrophobic lubricant film on granule surfaces. Tablet compression on a rotary press fitted with multi-tip tooling at a main compression force between 8 kN and 18 kN yields tablets with hardness in the range of 5–8 kp and friability less than 0.8% as measured according to USP <1216>. Dissolution testing conducted per USP <711> using Apparatus II (paddle method) at 75 rpm in 900 mL of simulated gastric fluid without pepsin (pH 1.2) typically demonstrates niclosamide release exceeding 70% at 45 minutes when the formulation contains sodium lauryl sulfate at 0.5–2.0% w/w as a wetting agent incorporated during the granulation phase. Content uniformity evaluated according to USP <905> requires an acceptance value AV ≤ 15.0 for both active pharmaceutical ingredients. Tablet disintegration tested per USP <701> in purified water at 37±2°C should occur within 15 minutes for immediate-release veterinary anthelmintic tablets; formulations failing this threshold generally require adjustment of the superdisintegrant system, typically crospovidone or sodium starch glycolate at 2–4% w/w incorporated intragranularly plus an additional 2% w/w extragranular fraction to achieve the desired disintegration kinetics without compromising tablet hardness.

Tablet formulations for companion animals combine the cestocidal activity of niclosamide with the nematocidal activity of piperazine in unit doses that vary by target species body weight class. Companion animal tablets marketed for canine use commonly contain niclosamide at 200–500 mg per tablet alongside piperazine (as citrate or adipate salt) equivalent to 100–200 mg piperazine base, but published data for specific commercial formulations is limited due to proprietary constraints. Compression tooling for oblong or scored veterinary tablets requires custom punch geometry with embossed score lines; the depth and profile of the score line must be validated for tablet splitting accuracy according to USP <905> uniformity of dosage units when split tablets comprise half of the labeled dose. Batch-to-batch variability in niclosamide crystal aspect ratio from different API suppliers affects granulation liquid uptake and subsequent tablet density; suppliers are therefore qualified with particle size distribution specifications including D10, D50, and D90 limits for the micronized or milled niclosamide input material.

For injectable dosage forms, the formulation constraints imposed by niclosamide's aqueous insolubility and thermal sensitivity establish a narrow processing window that separates viable sterile suspensions from batch rejections based on particle size growth, syringeability failure, or assay loss. Injectable niclosamide-piperazine formulations are predominantly developed as sterile aqueous suspensions rather than true solutions, because niclosamide cannot achieve therapeutic concentrations in aqueous vehicles without resorting to organic cosolvents whose concentrations would exceed acceptable toxicity thresholds for intramuscular or subcutaneous administration in food-producing animals and companion species. The active pharmaceutical ingredient is subjected to wet media milling using a bead mill charged with 0.3–0.5 mm zirconium oxide grinding media, with the mill chamber jacketed and cooled to maintain product temperature below 30°C throughout the size-reduction operation; uncontrolled temperature excursion in this step promotes niclosamide crystal growth on cooling and can shift the particle size distribution irreversibly toward oversize populations. Particle size distribution is controlled to D90 ≤ 5 µm and D50 ≤ 2 µm, because larger particles lead to unacceptable needle blockage with 21-gauge or 23-gauge syringe needles during field administration and may provoke injection site granuloma formation in treated animals. The milled suspension is stabilized with a non-ionic surfactant system, typically polysorbate 80 at 0.1–0.5% w/v combined with a wetting agent such as soya lecithin at 0.05–0.2% w/v, to prevent particle agglomeration during terminal storage and reconstitution after shipping-induced sedimentation. Terminal sterilization by autoclaving presents a critical incompatibility: niclosamide undergoes measurable hydrolytic degradation when exposed to steam sterilization at 121°C for 15 minutes in aqueous suspension because the alkaline pH generated by piperazine dissolution accelerates nucleophilic attack on the salicylanilide amide bond. Consequently, aseptic processing is the preferred route for formulations containing this combination, with all vehicle components passed through 0.22 µm sterilizing-grade membrane filters prior to final homogenization with the separately sterilized active powder. The vehicle for suspension typically comprises a buffered aqueous phase at pH 5.5–6.5 using citrate-phosphate buffer, within which piperazine exists predominantly in its protonated, water-soluble form while niclosamide remains largely undissociated but uniformly suspended. Syringeability testing per USP <787> requires the suspension to pass through a 21-gauge needle without clogging across multiple draw-up and expulsion cycles, and resuspendability testing after simulated shipping vibrations confirms that sedimented particles re-disperse within 10 seconds of manual shaking. Sterility testing per USP <71> and bacterial endotoxin testing per USP <85> with a limit of ≤ 0.5 EU/kg body weight are mandatory release criteria for injectable veterinary products. Published data for specific niclosamide-piperazine injectable products in commercial distribution is limited, and formulators should treat this dosage form as a non-standard presentation requiring justification in the relevant regulatory submission under VICH GL 51 or equivalent guidance.

Capsule Fill Weight Uniformity Depends on Powder Flow Property Thresholds

Capsule filling of niclosamide-piperazine powder blends subjects the API to a distinct set of process demands compared with tableting, primarily because capsule fill weight uniformity is governed by the bulk flow characteristics of the powder rather than by compressibility or granule strength. Niclosamide as received from synthesis typically exhibits a poured bulk density of 0.15–0.35 g/mL and a tapped bulk density of 0.40–0.60 g/mL, yielding a Carr index in the range of 35–45%, which classifies the material as poorly flowing and requires pre-processing before direct encapsulation on automated equipment. Piperazine citrate, selected over the free base for capsule and powder applications due to reduced hygroscopicity and improved solid-state stability, contributes a crystalline fraction with a more favorable flow profile but introduces its own challenges related to particle attrition during high-speed encapsulation and potential sticking to dosator surfaces. Blending of the two actives with diluents such as spray-dried lactose monohydrate (with D50 in the range of 90–110 µm) or microcrystalline cellulose grade PH-102 (with D50 in the range of 90–130 µm) at diluent fractions of 30–50% w/w adjusts the bulk flow properties into a range compatible with dosator-type capsule filling machines operating at 60,000–120,000 capsules per hour. Colloidal silicon dioxide at 0.25–0.5% w/w and magnesium stearate at 0.5–1.0% w/w are added as glidant and lubricant respectively, with blending time controlled to 3–5 minutes in a tumble blender to avoid segregation of the low-density niclosamide fraction that otherwise migrates to the top of the blend under prolonged rotational shear. Fill weight uniformity is verified according to USP <905> for weight variation across empty capsule shells, with acceptance criteria of ±7.5% for capsule weights below 300 mg and ±5% for capsule weights exceeding 300 mg. Hard gelatin capsules of size 0 or size 1 are typically employed for companion animal dosing, with shell moisture content maintained between 13% and 16% w/w to prevent embrittlement during high-speed filling at ambient relative humidity below 45%; operation above this humidity threshold induces shell softening and increases rejection rates on in-line checkweighing stations. Dissolution testing on filled capsules follows USP <711> Apparatus II equipped with stainless steel sinkers, because niclosamide-containing capsule fills may float when released into dissolution media without mechanical retention, producing artificially low release curves. In-line checkweighing on the capsule filling line rejects individual capsules outside ±5% of target fill weight, and metal detection with a threshold of 1.5 mm ferrous / 2.0 mm non-ferrous is employed as a standard contamination control measure on production-scale filling lines. Stability of niclosamide-piperazine capsules in primary packaging—HDPE bottles with induction-sealed liners or cold-form aluminum blister packs—is evaluated under ICH Q1A(R2) conditions at 40°C/75% RH for 6 months and 25°C/60% RH for 24 months, with assay and related substances monitored by validated HPLC-UV methods using reference standards qualified per USP monograph procedures.

Water-Dispersible Powder Reconstitution and Suspension Stability Metrics

Water-dispersible powders containing niclosamide-piperazine are formulated for administration via drinking water to poultry, swine, and occasionally pre-ruminant calves, where the critical performance attribute is not dissolution rate but rather the ability of the suspended niclosamide particles to remain uniformly distributed throughout the duration of medicated water consumption across flock or herd populations. The powder formulation requires micronization of niclosamide to a particle size distribution with D90 ≤ 25 µm, typically achieved through air-jet milling at a feed rate of 5–15 kg/h with an inlet air pressure of 6–8 bar, because particles exceeding this dimension sediment too rapidly in standing water troughs and produce inconsistent dosing across animals consuming at different times after mixing. Piperazine, whether supplied as the citrate or adipate salt, dissolves completely in the aqueous phase, establishing a solution concentration that is immediately bioavailable, while niclosamide remains as a suspended solid that must be maintained through the inclusion of wetting agents and viscosity-modifying agents. Sodium lignin sulfonate at 1–3% w/w, silica-based anti-caking agents at 0.5–1.5% w/w, and a food-grade thickening polymer such as xanthan gum at 0.1–0.3% w/v in the reconstituted suspension are standard components, but published data for specific commercial formulations is limited. The powder blend is produced by mixing micronized niclosamide, piperazine citrate, the dispersing agent, and the anti-caking agent in a ribbon blender or a double-cone blender; homogeneity testing according to GMP principles for medicated drinking water premixes requires sampling at 10 discrete points across the blend, with a relative standard deviation of ≤ 5.0% for both active markers determined by validated HPLC methods. Reconstitution testing simulates field use conditions: a 1 kg sample of powder is added to 100 L of potable water at 20°C in a standard drinker tank, stirred for 2 minutes, and suspension uniformity is measured by withdrawing samples from the top, middle, and bottom of the tank at 0, 2, 4, 6, and 8 hours post-mixing. Niclosamide concentration at the bottom sampling point must remain within 90–110% of the initial top-layer concentration at all time points; failure to meet this specification indicates insufficient suspending agent performance or an oversized particle distribution requiring further milling. Powder flowability is characterized by angle of repose measurements; values below 40° are generally acceptable for automated sachet filling equipment, whereas angles exceeding 45° require addition of glidant or re-evaluation of the finished moisture content. Moisture content of the finished powder is controlled to ≤ 2.0% w/w to prevent caking during storage at elevated humidity, and the product is packaged in polyethylene-lined multiwall paper bags or foil laminate pouches with desiccant sachets when storage durations exceed 12 months under tropical conditions exceeding 30°C/70% RH.

In fluid-bed top-spray granulation for feed incorporation, the API blend is fluidized and sprayed with an aqueous binder solution of polyvinylpyrrolidone K30 or gelatin at 5–10% w/w dissolved in purified water, producing granules that offer reduced dust generation compared with powders and improved compliance when mixed into pelleted or crumbled feed structures. The inlet air temperature is set to 60–65°C, balancing the need for rapid solvent evaporation against the thermal degradation threshold of niclosamide, and the product temperature is maintained below 45°C throughout the process as verified by in-line thermocouple measurement within the fluidized bed. Binder solution spray rate is controlled at 50–100 g/min per kilogram of bed loading, with atomization air pressure set at 1.5–2.5 bar to produce droplet sizes in the range of 50–100 µm, which ensures uniform granule growth without excessive wetting that would lead to agglomeration into unusable lumps and subsequent discharge through the bottom screen of the granulation chamber. Granule size distribution is controlled by classification: the target fraction falls between 150 µm and 1000 µm, with fines below 150 µm recycled at a ratio not exceeding 30% of fresh feed to avoid over-densification and attrition-induced particle morphology changes in the niclosamide fraction. Granule friability, measured by rotating 10 g of granules in a friabilator drum for 100 revolutions, remains below 5.0%, because excessive friability generates dust during subsequent feed mixing operations and contributes to cross-contamination within the feed mill. The granules are packed with a bulk density of 0.5–0.7 g/mL, a value that enables uniform blending into feed at inclusion rates as low as 0.1% w/w in final feed, equivalent to 1 kg of granules per ton of finished feed. Mixing validation studies conducted in horizontal ribbon mixers or paddle mixers at feed mills require that the coefficient of variation for niclosamide marker analysis does not exceed 10% after 5–10 minutes of mixing at nominal batch sizes ranging from 500 kg to 2000 kg. Carryover testing is performed per FDA 21 CFR 558 regulations and EU Regulation (EC) No. 183/2005 on medicated feed manufacturing, requiring analysis of the first subsequent non-medicated batch for niclosamide at levels above the detection limit of 5 ppm by HPLC-UV. Granule formulations for swine often target a final feed concentration of niclosamide at 50–100 ppm and piperazine at 500–1000 ppm, but published data for specific regional approvals is limited and formulators must confirm target species residue limits under VICH GL 49 guidance for residue depletion studies in food-producing animals.

When Feed Mill Homogeneity Testing Exceeds a Coefficient of Variation of 5%

Niclosamide-piperazine veterinary premix concentrates, typically manufactured at active concentrations of 5–10% w/w niclosamide and 10–20% w/w piperazine (expressed as salt), serve as the intermediate dilution step between bulk API and final medicated feed or drinking water preparations. The premix format places extraordinary demands on carrier selection and mixing equipment validation, because small deviations in premix homogeneity are amplified exponentially at final feed inclusion rates of 0.1–0.5% w/w, and a premix that passes visual inspection may nonetheless deliver subtherapeutic or supratherapeutic doses after downstream dilution. When a ribbon mixer produces premix batches with a coefficient of variation (CV) exceeding 5.0%, the root cause is generally traced to one of three factors: carrier particle size mismatch with the active particles, inadequate mixing time for the batch geometry, or electrostatic charge accumulation on micronized niclosamide fractions during transfer and blending operations. Carriers commonly employed include ground corn cob fractions with geometric mean diameter (GMD) of 200–500 µm, calcium carbonate with GMD of 50–150 µm, or microcrystalline cellulose with GMD of 90–130 µm. The selection of carrier is dictated by the density differential: niclosamide particles exhibit a true density of approximately 1.5 g/cm³, and carrier materials with particle density within ±0.3 g/cm³ of this value minimize segregation during bulk transfer and intermediate warehouse storage. Premix manufacture is validated through mixer efficiency studies conducted according to GMP guidance, in which 10–20 samples are withdrawn from specified locations within the mixer at multiple time points (e.g., 3, 5, 7, 10, and 15 minutes), and the assay results for both niclosamide and piperazine markers are evaluated for coefficient of variation and mean recovery. Acceptance criteria under EU Regulation (EC) No. 183/2005 and FDA 21 CFR 558.5 require CV ≤ 5.0% and mean assay values within 95–105% of the theoretical concentration for both active components. The premix is packaged in 25 kg multi-wall paper bags with polyethylene liners, and antistatic treatment of the packaging line environment to maintain relative humidity at 45–55% prevents static charge accumulation that otherwise causes niclosamide fines to adhere to the inner bag surfaces, depleting the first and last portions of each bag during feed mill use and creating systematic under-dosing at the beginning and end of each production run. Stability of premixes is evaluated under FEFAC (European Feed Manufacturers' Federation) recommendations: 6 months at 25°C/60% RH in the original sealed package, with potency retention of ≥ 90% for both actives measured by stability-indicating HPLC methods. Premix concentrates for niclosamide-piperazine are not permitted for use in animals producing milk or eggs for human consumption in several regulatory jurisdictions, and the withdrawal period in food-producing animals must be established from residue depletion studies per VICH GL 48 guidelines prior to marketing authorization.

Oral drench solutions for ruminants, particularly cattle and sheep, require administration volumes that are practical under field conditions—typically 5–20 mL per animal for sheep and 20–50 mL per animal for cattle—which imposes a minimum niclosamide concentration of 50–100 mg/mL in the final product. Niclosamide's intrinsic aqueous solubility of 5–8 mg/L at 25°C is insufficient by several orders of magnitude, necessitating the use of non-aqueous cosolvent systems combined with surfactant-mediated solubilization. Propylene glycol and polyethylene glycol 400 are the most commonly employed cosolvents, blended at ratios of 50–80% v/v with purified water, in which niclosamide solubility increases to 15–25 mg/mL at ambient temperature; the remainder of the solubilization burden is addressed by micellar incorporation using polysorbate 80 at 10–20% w/v combined with a cosurfactant such as propylene glycol monocaprylate at 2–5% w/v, producing a microemulsion or micellar solution with aggregate diameters below 100 nm as characterized by dynamic light scattering. Piperazine, supplied as the citrate salt, dissolves readily in the aqueous-cosolvent blend, and the final solution pH is adjusted to 6.0–6.5 using citric acid or sodium citrate solutions, because alkaline pH promotes hydrolysis of niclosamide via nucleophilic attack on the salicylanilide amide bond, with measurable degradation products accumulating above pH 7.5 during accelerated stability testing. Viscosity of the drench solution must remain below 50 mPa·s at 20°C to permit accurate metering through standard drench applicator guns and to avoid excessive residue retention on the oral mucosa that would reduce the effective delivered dose. Solution clarity is maintained by filtration through 10 µm polypropylene cartridge filters during manufacture, with integrity testing of the filter housing performed per manufacturer protocols. Chemical stability studies conducted under ICH Q1B photostability conditions reveal that niclosamide is susceptible to photodegradation in clear solution formulations, with losses exceeding 10% after cumulative exposure of 1.2 million lux·hours of visible light and 200 watt·hours/m² of near-UV radiation; consequently, primary packaging for drench solutions employs amber-colored high-density polyethylene bottles or aluminum foil overwraps to exclude actinic light. Dose accuracy testing per ISO 10953:2019 evaluates the delivery volume of the drench applicator at multiple settings across the intended dosing range, with relative standard deviation across 10 replicates required to be ≤ 2.0%. Chemical compatibility between the solution and the wetted components of the applicator—seals, piston materials, and nozzle inserts—must be assessed through extraction testing per USP <1661> guidance to prevent leaching of elastomeric compounds into the product and to verify that no formulation component degrades the applicator materials over the product shelf life. Published data for specific commercially available niclosamide-piperazine drench solution formulations is limited, and regulatory submissions in the European Union require compliance with VICH GL 51 regarding pharmaceutical quality for veterinary medicinal products, including documentation of the container-closure system under ICH Q1A(R2) stability protocols.